AstraZeneca Cuts Innate-Partnered Phase 3 Trial In Head & Neck Cancer

  • Innate Pharma SA’s IPHA futility interim analysis of the INTERLINK-1 Phase 3 study sponsored by AstraZeneca Plc AZN did not meet a pre-defined threshold for efficacy
  • Based on this result and the recommendation of an Independent Data Monitoring Committee, AstraZeneca has informed Innate that the study will be discontinued. 
  • There were no new safety findings. AstraZeneca plans to share the data in due course.
  • Related: Innate Pharma Says Chemo-Free Monalizumab Triplet Therapy Shows Preliminary Anti-Cancer Activity.
  • The INTERLINK-1 study evaluated monalizumab in combination with cetuximab vs. cetuximab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
  • Monalizumab is being studied in a Phase 3 study sponsored by AstraZeneca, evaluating durvalumab in combination with monalizumab or AstraZeneca’s oleclumab (anti-CD73) in patients with unresectable, Stage III non-small cell lung cancer.
  • Price Action: IPHA shares are down 16.3% at $2.68 during the premarket session on the last check Monday.

Image and article originally from Read the original article here.